000K utf8 1100 2022$c2022-06-29 1500 eng 2050 urn:nbn:de:hbz:465-20231121-093312-0 2051 10.1002/ehf2.14019 3000 Hendricks, Stefanie 3010 Balcer, Bastian 3010 Dykun, Iryna 3010 Mahabadi, A. Abbas 3010 Rassaf, Tienush 3010 Totzeck, Matthias 4000 Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure$da meta‐analysis [Hendricks, Stefanie] 4209 Aims: The initial and dynamic levels of B-type natriuretic peptide (BNP) and N-terminal-prohormone BNP (NT-proBNP) are routinely used in clinical practice to identify patients with acute and chronic heart failure. In addition, BNP/NT-proBNP levels might be useful for risk stratification in patients with and without heart failure. We performed a meta-analysis to investigate, whether the value of BNP/NT-proBNP as predictors of long-term prognosis differentiates in cohorts with and without heart failure. Methods and results: We systematically searched established scientific databases for studies evaluating the prognostic value of BNP or NT-proBNP. Random effect models were constructed. Data from 66 studies with overall 83 846 patients (38 studies with 46 099 patients with heart failure and 28 studies with 37 747 patients without heart failure) were included. In the analysis of the log-transformed BNP/NT-proBNP levels, an increase in natriuretic peptides by one standard deviation was associated with a 1.7-fold higher MACE rate (hazard ratio [95% confidence interval]: 1.74[1.58–1.91], P < 0.0001). The effect sizes were comparable, with a substantial overlap in the confidence intervals, when comparing studies involving patients with and without heart failure (1.75[1.54–2.0], P < 0.0001 vs. 1.74[1.47–2.06], P < 0.0001). Similar results were observed when stratifying by quartiles of BNP/NT-proBNP. In studies using pre-defined cut-off-values for BNP/NT-proBNP, elevated levels were associated with the long-term prognosis, independent of the specific cut-off value used. Conclusions: BNP/NT-proBNP levels are predictors for adverse long-term outcome in patients with and without known heart failure. Further research is necessary to establish appropriate thresholds, especially in non-heart failure cohorts. 4950 https://doi.org/10.1002/ehf2.14019$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:hbz:465-20231121-093312-0$xR$3Volltext$534 4961 https://duepublico2.uni-due.de/receive/duepublico_mods_00078906 5051 610 5550 BNP 5550 General population cohorts 5550 NT-proBNP 5550 Prognosis